SPOTLIGHT: Breast cancer vaccine posts positive data

Researchers report that Apthera's NeuVax breast cancer vaccine significantly reduced the risk of reoccurrence in patients expressing the HER2-neu protein. And it reduced mortality among a group of women with low or intermediate expression of the protein by 100 percent. Report

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.